nitrofurantoin has been researched along with phenobarbital in 24 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (45.83) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (33.33) | 29.6817 |
2010's | 5 (20.83) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duffy, EM; Jorgensen, WL | 1 |
Topliss, JG; Yoshida, F | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bonow, A; Bräunlich, H; Schröter, S | 1 |
Boyd, MR; Sasame, HA; Stiko, AW | 1 |
Barzaghi, D; Salvaterra, M; Setnikar, I; Veronese, M | 1 |
Ballatori, N; Truong, AT | 1 |
Behrens, BC; Bryan, GT; Ichikawa, M; Wang, CY | 1 |
Ganshorn, A; Kurz, H | 1 |
Kaeser, HE | 1 |
Burba, JV | 1 |
Jonen, HG; Kaufmann, I | 1 |
BAKER, L; KAHN, SB; LISCHNER, H; WILLIAMS, WJ | 1 |
1 review(s) available for nitrofurantoin and phenobarbital
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
23 other study(ies) available for nitrofurantoin and phenobarbital
Article | Year |
---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Age-dependence of renal tubular reabsorption of nitrofurantoin.
Topics: Absorption; Aging; Animals; Diuresis; Female; Hydrogen-Ion Concentration; Kidney Tubules; Nitrofurantoin; Phenobarbital; Probenecid; Rats | 1978 |
Metabolic activation of nitrofurantoin--possible implications for carcinogenesis.
Topics: Aerobiosis; Anaerobiosis; Animals; Biotransformation; Carcinogens; Flavin-Adenine Dinucleotide; Lung; Male; Microsomes; Microsomes, Liver; NADP; Nitrofurantoin; Phenobarbital; Rats; Rats, Inbred Strains; Tissue Distribution | 1979 |
Effects of different drugs on the urinary excretion of nifurpipone (NP) and of nitrofurantoin (NTF) in the rat.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Drug Interactions; Hydrochlorothiazide; Male; Nitrofurans; Nitrofurantoin; Phenobarbital; Proadifen; Probenecid; Quinine; Rats; Time Factors | 1975 |
Relation between biliary glutathione excretion and bile acid-independent bile flow.
Topics: Aminopyrine; Animals; Arsenic; Arsenites; Benzylamines; Bile; Bile Acids and Salts; Buthionine Sulfoximine; Cefamandole; Furosemide; Glutathione; Glycocholic Acid; Kinetics; L-Lactate Dehydrogenase; Liver; Male; Methionine Sulfoximine; Nitrofurantoin; Phenobarbital; Rats; Rats, Inbred Strains; Sodium Compounds; Taurocholic Acid | 1989 |
Nitroreduction of 5-nitrofuran derivatives by rat liver xanthine oxidase and reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase.
Topics: Acetamides; Allylisopropylacetamide; Animals; Carbon Radioisotopes; Chromatography, Ion Exchange; Cytochrome c Group; Cytochrome Reductases; Cytosol; Dialysis; Electron Transport; Female; Hydrazines; In Vitro Techniques; Liver; Methylcholanthrene; Microsomes, Liver; Milk; NADP; Nitrofurans; Nitrofurantoin; Oxidation-Reduction; Phenobarbital; Protein Binding; Rats; Thiazoles; Xanthine Oxidase | 1974 |
[Differences between the protein binding of newborns and adults and their importance for pharmacological action].
Topics: Acetaminophen; Age Factors; Aminosalicylic Acids; Atropine; Chloramphenicol; Humans; Infant, Newborn; Isoniazid; Methicillin; Morphine; Nitrofurantoin; Oxyphenbutazone; Phenacetin; Phenobarbital; Phenytoin; Promethazine; Protein Binding; Salicylates; Sulfadimethoxine; Thiopental | 1968 |
[Neurotoxicity of drugs].
Topics: Arsenic; Drug-Related Side Effects and Adverse Reactions; Humans; Nervous System Diseases; Nitrofurantoin; Penicillins; Phenobarbital; Phenytoin; Sulfonamides; Vincristine | 1972 |
Non-equivalent preparations of the same drug.
Topics: Chloramphenicol; Dosage Forms; Humans; Nitrofurantoin; Oxytetracycline; Pharmaceutical Preparations; Phenindione; Phenobarbital; Phenylbutazone; Phenytoin; Tetracycline; Therapeutic Equivalency; Tolbutamide; Warfarin | 1971 |
Influence of several drugs on the in vivo and in vitro activity of mammalian hepatic azo-reductase.
Topics: Animals; Caffeine; Guanethidine; Guinea Pigs; In Vitro Techniques; Iproniazid; Isoniazid; Liver; Nitrofurantoin; Oxidoreductases; Pentylenetetrazole; Phenobarbital; Phenylbutazone; Phenytoin; Rabbits; Rats; Sulfinpyrazone; Sulfonic Acids; Trimethadione | 1968 |
Enhanced biotransformation of nitrofurantoin in rats after induction with 3-methylcholanthrene or beta-naphthoflavone.
Topics: Aerobiosis; Animals; beta-Naphthoflavone; Biotransformation; Enzyme Induction; Flavonoids; In Vitro Techniques; Male; Methylcholanthrene; Microsomes, Liver; Nitrofurantoin; Phenobarbital; Rats | 1980 |
MEGALOBLASTIC ANEMIA ASSOCIATED WITH THE INGESTION OF PHENOBARBITAL AND PRIMIDONE. REPORT OF A CASE IN A SIX-YEAR-OLD CHILD.
Topics: Anemia, Aplastic; Anemia, Macrocytic; Anemia, Megaloblastic; Anti-Bacterial Agents; Barbiturates; Candidiasis, Vulvovaginal; Child; Chloramphenicol; Epilepsy; Esophageal Stenosis; Intellectual Disability; Nitrofurantoin; Periodontal Diseases; Phenobarbital; Primidone; Sulfonamides; Toxicology | 1963 |